Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • scubachris
    Junior Member
    • Jan 2011
    • 8

    #1

    Ion Torrent Proton PII-PIII Chips?

    Hello,

    apologies about the simplicity of the question but I'm a bit out of the loop and I couldn't find any relevant info online. Back in 2013 I used to work at a lab that had an Ion Torrent Proton, and I remember reading about the upcoming PII and PIII chips that supposedly had much higher throughput than the PI. Does anybody know what happened to them? Has the Proton been completely replaced by other instruments?
    Thanks in advance.
  • Bukowski
    Senior Member
    • Jan 2010
    • 388

    #2
    I'm not sure the PII chip ever saw the light of day. The platform was effectively discontinued with the launch of the S5:



    And depending on your use case they may be better platforms on the market

    Comment

    • r.rosati
      Member
      • Aug 2015
      • 95

      #3
      I work in a lab with an Ion Proton.
      Despite chats that "some laboratories" were already testing it, the PII chip was never released.
      What was released, for the new S5 platform, is the Ion 550 chip; which should generate 100-130 million reads, as opposed to the 60-80M "official" reads for the PI (although we constantly get 80-90M reads on PI chips). This is not a chip that allows human genome testing as "promised"; it's just a chip that somehow comfortably fits 3 exomes instead of PI's 2 exomes per chip.
      As of the platform:
      Within the scientific community, my feeling is that it has definitely fallen out of grace in research settings. And whatever grace there ever was, I must say. This is mostly because the platform shows non-random errors, located at specific sites (including but not limited to homopolymer sites) which makes those sites basically un-testable with the technology. Thermo is still trying to reduce this issue. The new Hi-Q kits perform quite better, but the problem persists. And lately, Thermo made some adjustments to their software which look more of a "hiding errors under a rug" instead of actually trying to improve the technology; which was a bit worrying to witness. They recently introduced "effective regions" in their targets file, aka the variant caller plugin will simply cut away and ignore any portion of reads that fall in introns just a bit farther than the splice donor and acceptor sites, in hope of ignoring lots of homopolymer regions within introns. Thermo also recently increased - in my opinion, a bit silently - the minimum number of reads needed to call a variant in their standard VariantCaller parameters, from 10 to 35-40 minimum reads. I'm not a big fan of this, as I prefer to filter away a false positive than to get a false negative. I only noticed it 6 months after the change; so now we have to apply one custom parameter instead of relying on the (in theory, optimized) factory-suggested ones.
      In diagnostic settings, Thermo has a few aces up their sleeve with Ampliseq, but Thermo & Illumina made a deal so that Ampliseq technology can now be used on Illumina. This is good for Thermo, but unfortunately the prices for kits have spiked a bit, so much that for a small lab, having an S5 or Ion Proton can be pointless unless you can wrestle some discounts; it's just cheaper and better to outsource and send your samples to be sequenced with an HiSeq.
      Last edited by r.rosati; 06-14-2019, 05:16 AM.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Today, 02:55 AM
      0 responses
      6 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      11 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      12 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      24 views
      0 reactions
      Last Post SEQadmin2  
      Working...